DJ Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
23-Oct-2025 / 15:02 GMT/BST
=----------------------------------------------------------------------------------------------------------------------
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
The Vanguard Group,
a. Full name of discloser Inc.
b. Owner or controller of interests and short positions disclosed, if different from
1(a)
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
c. Name of offeror/offeree in relation to whose relevant securities this form
relates Avadel Pharmaceuticals
plc
Use a separate form for each offeror/offeree
d. If an exempt fund manager connected with an offeror/offeree, state this and
specify identity of offeror/offeree (Note 1)
e. Date position held/dealing undertaken
22 October 2025
For an opening position disclosure, state the latest practicable date prior to the disclosure
f. In addition to the company in 1(c) above, is the discloser also making
disclosures in respect of any other party to the offer? N/A
If it is a cash offer or possible cash offer, state "N/A"
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security USUSD0.01 ordinary shares
(Note 3)
Interests Short positions
Number % Number %
1. Relevant securities owned and/or controlled 5,525,469 5.67%
2. Cash-settled derivatives
3. Stock-settled derivatives (including options) and agreements to
purchase/ sell
Total 5,525,469 5.67%
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1 (c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Purchase/sale
Price per unit
Class of relevant security Number of securities (Note 5)
Ap29
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price
relevant description e.g. opening/ closing a long/ short position, increasing/ reducing a reference per unit
security e.g. CFD long/ short position securities (Note 5)
(Note 6)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Number
Product of Exercise Type Option
Class of description e.g. Writing, purchasing, securities price e.g. Expiry money
relevant call selling, varying to which per American, date paid/
security option etc. option unit European received per unit
relates etc.
(Note 6)
(ii) Exercise
Class of Product Exercising/ Exercise
relevant description exercised Number of price per
security e.g. call against securities unit
option (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of Nature of dealing Price per unit (if relevant e.g. subscription, Details applicable) security conversion, exercise (Note 5) Not Applicable
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" none
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. none
(c) Attachments
Is a Supplemental Form 8 attached? No Date of disclosure 23 October 2025 Contact name Shawn Acker Telephone number 001-610-669-6713
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
-----------------------------------------------------------------------------------------------------------------------
Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
Category Code: RET - Avadel Pharmaceuticals plc TIDM: IRSH LEI Code: 5493002789CX3L0CJP65 Sequence No.: 406057 EQS News ID: 2217888 End of Announcement EQS News Service =------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2217888&application_name=news&site_id=dow_jones%7e%7e%7ebed8b539-0373-42bd-8d0e-f3efeec9bbed
(END) Dow Jones Newswires
October 23, 2025 10:03 ET (14:03 GMT)